Industry
Biotechnology
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 11:10 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:07 am
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 5:42 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 9:35 pm
Portfolio Pulse from Benzinga Newsdesk
August 02, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
July 22, 2024 | 11:43 am
Portfolio Pulse from Benzinga Newsdesk
June 21, 2024 | 5:40 pm
Portfolio Pulse from Benzinga Newsdesk
June 21, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 4:40 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 12:16 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.